Risk of Malignancy With Vedolizumab vs TNF-α Antagonists in Patients With IBD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Digestive Diseases and Sciences
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Risk of Malignancy With Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients With Inflammatory Bowel Diseases
Dig. Dis. Sci. 2021 Jun 03;[EPub Ahead of Print], S Singh, HC Heien, L Sangaralingham, ND Shah, WJ SandbornFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.